BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Prognosis
86 results:

  • 1. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy.
    Cordero-Hernandez IS; Ross AC; Dasari A; Halperin DM; Chasen B; Yao JC
    Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38329269
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Coexistence of longitudinally extensive transverse myelitis and diffuse midline glioma in the brainstem in an adolescent boy with acute flaccid paralysis.
    Caliskan E; Sager SG; Yukselmis U; Kilic AK; Gunbey HP
    Childs Nerv Syst; 2024 Jan; 40(1):227-232. PubMed ID: 37737897
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
    Znaider VK; Mikkelsen LH; Jensen CFS; Sønksen J; Heegaard S
    Scand J Urol; 2023 Aug; 58():52-59. PubMed ID: 37635444
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine tumors and Metastases.
    Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
    Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
    Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
    BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The genetic alterations of rectal neuroendocrine tumor and indications for therapy and prognosis: a systematic review.
    Li K; Liu Y; Han J; Gui J; Zhang X
    Endocr J; 2023 Feb; 70(2):197-205. PubMed ID: 36403965
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. tumor-specific radiosensitizing effect of the atm inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts.
    Scheper J; Hildebrand LS; Faulhaber EM; Deloch L; Gaipl US; Symank J; Fietkau R; Distel LV; Hecht M; Jost T
    Strahlenther Onkol; 2023 Dec; 199(12):1128-1139. PubMed ID: 36229655
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Potential mechanisms underlying the promoting effects of 3D collagen scaffold culture on stemness and drug resistance of glioma cells.
    Jia W; Zhu H; Zhao M; Zhou Q; Yin W; Liu W; Wang L; Xiao Z; Jiang X; Dai J; Ren C
    Biochim Biophys Acta Mol Basis Dis; 2022 Nov; 1868(11):166522. PubMed ID: 35981653
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Role of diffusion-weighted imaging in differentiating angiomatous meningioma from atypical meningioma.
    Liu X; Wang Y; Wei J; Li S; Xue C; Deng J; Liu H; Sun Q; Zhang X; Zhou J
    Clin Neurol Neurosurg; 2022 Oct; 221():107406. PubMed ID: 35932585
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Next-Generation Grade and Survival Expression Biomarkers of Human Gliomas Based on Algorithmically Reconstructed Molecular Pathways.
    Zolotovskaia MA; Kovalenko MA; Tkachev VS; Simonov AM; Sorokin MI; Kim E; Kuzmin DV; Karademir-Yilmaz B; Buzdin AA
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806337
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis.
    Melone V; Salvati A; Palumbo D; Giurato G; Nassa G; Rizzo F; Palo L; Giordano A; Incoronato M; Vitale M; Mian C; Di Biase I; Cristiano S; Narciso V; Cantile M; Di Mauro A; Tatangelo F; Tafuto S; Modica R; Pivonello C; Salvatore M; Colao A; Weisz A; Tarallo R
    J Transl Med; 2022 Jul; 20(1):306. PubMed ID: 35794609
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients.
    Shi X; Li H; Xu Y; Nyalali AMK; Li F
    Neurol Sci; 2022 Sep; 43(9):5523-5531. PubMed ID: 35606674
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma.
    Kaptein FHJ; Stals MAM; Kapteijn MY; Cannegieter SC; Dirven L; van Duinen SG; van Eijk R; Huisman MV; Klaase EE; Taphoorn MJB; Versteeg HH; Buijs JT; Koekkoek JAF; Klok FA
    J Thromb Haemost; 2022 Jul; 20(7):1665-1673. PubMed ID: 35460331
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy.
    Schnöller LE; Albrecht V; Brix N; Nieto AE; Fleischmann DF; Niyazi M; Hess J; Belka C; Unger K; Lauber K; Orth M
    Radiat Oncol; 2022 Apr; 17(1):79. PubMed ID: 35440003
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Detection of disease-causing mutations in prostate cancer by NGS sequencing.
    Mangolini A; Rocca C; Bassi C; Ippolito C; Negrini M; Dell'Atti L; Lanza G; Gafà R; Bianchi N; Pinton P; Aguiari G
    Cell Biol Int; 2022 Jul; 46(7):1047-1061. PubMed ID: 35347810
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. atm germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications.
    El Jabbour T; Misyura M; Cowzer D; Zimmermann M; Rimkunas V; Marra A; Derakhshan F; Selenica P; Parilla M; Setton JS; Ceyhan-Birsoy O; Kemel Y; Catchings A; Ranganathan M; Ku GY; Janjigian YY; Zinda M; Koehler M; Stadler Z; Shia J; Reis-Filho JS; Mandelker D
    J Natl Cancer Inst; 2022 May; 114(5):761-770. PubMed ID: 35078243
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Mitochondrial DNA sequence variation and risk of glioma.
    Samanic CM; Teer JK; Thompson ZJ; Creed JH; Fridley BL; Burt Nabors L; Williams SL; Egan KM
    Mitochondrion; 2022 Mar; 63():32-36. PubMed ID: 35032707
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
    Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Biomarkers for prognosis in pancreatic neuroendocrine tumors.
    Zhu M; Sorenson KR; Liu R; Gould Rothberg BE; Halfdanarson TR
    Endocr Relat Cancer; 2021 Oct; 28(12):773-782. PubMed ID: 34582360
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Pathogenic atm Variant-Harbouring Well-Differentiated Aggressive Type 1 Gastric Neuroendocrine Tumour with High-grade Features (G3 NET): a New Addition to the Clinical and Pathological Spectrum of Gastric Neuroendocrine Neoplasms.
    Nassereddine H; Chicaud M; Rebah K; Théou-Anton N; Sautet A; Dermer J; Couvelard A
    Endocr Pathol; 2021 Dec; 32(4):517-523. PubMed ID: 34019237
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.